← Back to screener

Karyopharm Therapeutics Inc. KPTI

Rank #1616 · Nasdaq · $0.0B market cap
⚠ Going-concern flag — the auditor (Ernst & Young LLP) raised substantial doubt about this company's ability to continue operating in the latest filing. Read the actual filing before drawing conclusions.
Score
45.5
P/E
-0.1
P/B
-0.90
ROE
859.1%
Op. Margin
-88.7%
Debt Ratio
-2104%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -0.1x, P/B -0.90x. Ranks in the top 100% of the universe.

Profitability ★★★☆☆
Average

ROE 859.1%. Ranks in the top 45% of the universe.

Safety ★★★★★
Excellent

Debt ratio -2104%. Ranks in the top 1% of the universe. Under 100% is generally considered a safe level.

Growth ★☆☆☆☆
Weak

Revenue decline of 7.0% year over year. Ranks in the top 79% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2013–$-0.0B–$-0.0B–-832
2014–$-0.0B$-0.0B$-0.0B–-26
2015–$-0.0B$-0.0B$-0.0B–-49
2016–$-0.1B$-0.1B$0.2B–11
2017–$-0.1B$-0.1B$0.2B–9
2018$0.0B$-0.1B$-0.1B$0.2B-71903.926
2019$0.0B$-0.1B$-0.1B$0.2B-8133.297
2020$0.0B$-0.2B$-0.2B$0.1B-593.0189
2021$0.0B$-0.2B$-0.2B$0.2B-462.9143
2022$0.1B$-0.2B$-0.2B$0.0B-159.0773
2023$0.2B$-0.1B$-0.1B$0.1B-46.8742
2024$0.2B$-0.1B$-0.2B$-0.1B-90.5-473
2025$0.1B$-0.1B$-0.1B$-0.0B-88.7-2104

← See the full screener